세계의 반려동물 건강 시장 - 규모, 점유율, 동향 분석 보고서 : 동물별, 제품별, 유통 채널별, 최종 용도별, 지역별, 부문 예측(2024-2030년)

Companion Animal Health Market Growth & Trends:

The global companion animal health market size is expected to reach USD 42.50 billion by 2030, registering a CAGR of 9.3% over the forecast period, according to a new report by Grand View Research, Inc. The market is driven by rising research and development programs, growing numbers of government initiatives, increasing adoption of pets, and high volumes of veterinary surgeries & prevalence of chronic diseases in companion animals.The veterinary healthcare sector has experienced many challenges during the COVID-19 pandemic.Veterinarians could still work despite the shutdown. According to a survey of more than 3,000 pet owners in the U.S., UK, France, and Brazil, more than a quarter of pet owners have put off or avoided contacting their veterinarians since the pandemic started due to the fear of disease transmission.

Moreover, the majority of owners (65 percent) concur that the pandemic had no negative effects on access to medications and procedures.An increase in pet ownership is one of the major factors driving the market. Approximately 70% of households (90.5 million homes) in the U.S. have a pet, with dogs and cats being the most common breeds, according to the American Veterinary Medical Association. The market is also being driven by rising demand for pet medicine as more individuals own pets. The market for companion animal medication is also being driven by an increase in the demand for high-quality veterinarian care. Veterinary research and development activities have steadily increased during the last decade. There were numerous innovations in the fields of surgery and specialized medications for use in pets. To establish themselves as market leaders, major players are strategically integrating novel technologies.

For instance, in January 2022, the FDA approved Zoetis' first monoclonal antibody treatment for osteoarthritis, Solensia, which is intended to reduce pain in cats with the condition. Similar to this, the company has released Librela, a monoclonal antibody to lessen canine arthritic pain.In recent years, pet disease prevalence has increased in countries like France, which has increased the demand for pet treatment. Obesity, dental issues, skin allergies, osteoarthritis, and viral diseases are the most typical pet illnesses in France. The need for medications and preventive care to keep pets healthy and happy is highlighted by the rising prevalence of pet ailments in France. In addition, it is projected that the rising pharmaceutical and vaccine demand will further boost the market. The presence of government agencies that ensure the safety of veterinary pharmaceuticals, such as the French Agency for Veterinary Medicinal Products (ANMV), contributes to the growth of the market.

Companion Animal Health Market Report Highlights:

• By product, the pharmaceuticals segment held a dominant share of over 44.43% in 2023. The introduction of medications to aid in extending animal lifespan has been accelerated by a notable rise in pet ownership
• The dogs segment dominated the market with a share of over 40.0% in 2023 as a result of rising pet healthcare costs, particularly in developed regions
• By distribution channel, the hospital pharmacies segment held the largest share of over 47% in 2023.The global availability of veterinary clinics and hospital services has increased due to the rising pet adoption rate
• The hospitals & clinics end-use segment held a dominant share of over 80% in 2023. This is due to an expansion of veterinary hospitals and clinics with innovative infrastructure around the world. Another aspect influencing the segment growth is a rise in the number of veterinarians
• North America held a 35.82% share of the overall market in 2023

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Animal
  • 1.2.2. Product
  • 1.2.3. Distribution Channel
  • 1.2.4. End-Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Animal Outlook
  • 2.2.2. Product Outlook
  • 2.2.3. Distribution Channel Outlook
  • 2.2.4. End-use Outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Companion Animal Health Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing pet ownership
    • 3.2.1.2. The rise of pet insurance
    • 3.2.1.3. Growing preference for personalized pet care
    • 3.2.1.4. Advancements in animal healthcare technology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of advanced veterinary treatments
    • 3.2.2.2. Increasing cost of animal testing and veterinary care
• 3.3. Companion Animal Health Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Companion Animal Health Market: Treatment Estimates & Trend Analysis

• 4.1. Global Companion Animal Health Market: Animal Dashboard
• 4.2. Global Companion Animal Health Market: Animal Movement Analysis
• 4.3. Global Companion Animal Health Market by Animal, Revenue
• 4.4. Dogs
  • 4.4.1. Dogs market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Equine
  • 4.5.1. Equine market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Cats
  • 4.6.1. Cats market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Companion Animal Health Market: Product Estimates & Trend Analysis

• 5.1. Global Companion Animal Health Market: Product Dashboard
• 5.2. Global Companion Animal Health Market: Product Movement Analysis
• 5.3. Global Companion Animal Health Market Estimates and Forecasts, By Product, Revenue (USD Million)
• 5.4. Vaccines
  • 5.4.1. Vaccines market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Pharmaceuticals
  • 5.5.1. Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. OTC
    • 5.5.2.1. OTC market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Prescription
    • 5.5.3.1. Prescription market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Feed Additives
  • 5.6.1. Feed Additives market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Diagnostics
  • 5.7.1. Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Companion Animal Health Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Companion Animal Health Market: Distribution Channel Dashboard
• 6.2. Global Companion Animal Health Market: Distribution Channel Movement Analysis
• 6.3. Global Companion Animal Health Market Estimates and Forecasts by Distribution Channel, Revenue (USD Million)
• 6.4. Retail
  • 6.4.1. Retail market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. E-commerce
  • 6.5.1. E-commerce market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hospital pharmacies
  • 6.6.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Companion Animal Health Market: End -use Estimates & Trend Analysis

• 7.1. Global Companion Animal Health Market: End-use Dashboard
• 7.2. Global Companion Animal Health Market: End-use Movement Analysis
• 7.3. Global Companion Animal Health Market Estimates and Forecasts End-use, Revenue (USD Million)
• 7.4. Point-of-care/ In-house testing
  • 7.4.1. Point-of-care/ In-house testing estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Hospitals & clinics
  • 7.5.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Companion Animal Health Market: Regional Estimates & Trend Analysis by Animal, Product, Distribution Channel and End-use

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key customers
  • 9.2.3. Key company market share analysis, 2023
• 9.3. Company Profile
  • 9.3.1. Agrolabo S.p.A
    • 9.3.1.1. Company overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Product benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. Boehringer Ingelheim International GmbH
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Ceva
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Elanco
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. IDEXX Laboratories, Inc.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Indian Immunologicals Ltd.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Merck & Co., Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Norbrook
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Vetoquinol
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Virbac
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Zoetis Services LLC
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives